Medigene AG Announces KRAS G12V as First Target for TCR-guided T Cell Engagers
09 déc. 2024 05h00 HE
|
Medigene AG
Planegg/Martinsried, December 9, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Medigene Receives Milestone Payment from Regeneron Pharmaceuticals, Inc.
03 déc. 2024 05h00 HE
|
Medigene AG
Payment triggered by development milestone achieved by Regeneron’s collaborator in China, JW TherapeuticsProgresses first clinical use of Medigene’s End-to-End Platform to generate potentially...
Medigene AG Announces Refocus of Corporate Strategy and Organizational Realignment
26 nov. 2024 08h00 HE
|
Medigene AG
Planegg/Martinsried, November 26, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided...
Medigene Presents Data on an Innovative IFN-γ Biosensor Technology at SITC 2024
12 nov. 2024 07h00 HE
|
Medigene AG
Planegg/Martinsried, November 12, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Medigene Presents Latest Data on UniTope & TraCR Technology at PEGS and SITC 2024
11 nov. 2024 07h00 HE
|
Medigene AG
Planegg/Martinsried, November 11, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Medigene Presents Unique Approach for Use of Optimal T Cell Receptors in TCR-Guided Modalities at Cell 2024
08 nov. 2024 09h30 HE
|
Medigene AG
Members of Medigene management as expert speakers, Prof. Dolores Schendel, Chief Scientific Officer and Kirsty Crame, MD, Vice President, Clinical Strategy & DevelopmentPresentations and seminars...
Medigene to Present at Upcoming Investor Conferences
29 oct. 2024 06h30 HE
|
Medigene AG
Planegg/Martinsried, October 29, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Medigene AG reports Financial Results and Business Update for Q3 2024
24 oct. 2024 01h30 HE
|
Medigene AG
Planegg/Martinsried, October 24, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Medigene presents UniTope and TraCR a universal detection system for 3S recombinant TCRs at ASGCT 2024
17 oct. 2024 05h30 HE
|
Medigene AG
Planegg/Martinsried, October 17, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Medigene to Present at Upcoming Scientific Conferences
16 oct. 2024 05h30 HE
|
Medigene AG
Planegg/Martinsried, October 16, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...